Dapagliflozin propanediol is a pharmaceutical compound primarily used in the management of type 2 diabetes mellitus. It belongs to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors, which function by preventing the reabsorption of glucose in the kidneys, thereby promoting its excretion in urine and lowering blood glucose levels. The compound is characterized by its molecular structure, which includes a dapagliflozin moiety linked to a propanediol unit. This structural configuration enhances its pharmacological properties and bioavailability. Dapagliflozin propanediol is typically administered orally and is known for its efficacy in improving glycemic control, as well as providing additional benefits such as weight loss and potential cardiovascular protection. Its safety profile is generally favorable, although it may be associated with side effects such as urinary tract infections and dehydration. As with any medication, it is essential for patients to consult healthcare professionals for personalized advice and monitoring during treatment.

Dapagliflozin Propanediol

1971128-01-4: Dapagliflozin propanediol is a pharmaceutical compound primarily used in the management of type 2 diabetes mellitus. It belongs to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors, which function by preventing the reabsorption of glucose in the kidneys, thereby promoting its excretion in urine and lowering blood glucose levels. The compound is characterized by its molecular structure, which includes a dapagliflozin moiety linked to a propanediol unit. This structural configuration enhances its pharmacological properties and bioavailability. Dapagliflozin propanediol is typically administered orally and is known for its efficacy in improving glycemic control, as well as providing additional benefits such as weight loss and potential cardiovascular protection. Its safety profile is generally favorable, although it may be associated with side effects such as urinary tract infections and dehydration. As with any medication, it is essential for patients to consult healthcare professionals for personalized advice and monitoring during treatment.

CAS 1971128-01-4

Dapagliflozin Propanediol

Dapagliflozin Propanediol

Ref: 4Z-D-6250

Dapagliflozin Propanediol

Ref: ST-EA-CP-D8002